Home > Latest News on ID > Infectious Disease News
IDSA steps up commitment to 10 new antibiotics by 2020
Date: 2010-03-30   Read: 161121

IDSA steps up commitment to 10 new antibiotics by 2020

The Infectious Diseases Society of America formally outlined a challenge for global leaders to develop 10 new antimicrobial drugs by 2020 in a statement published online in Clinical Infectious Diseases.

The aim is to discover new drug classes, explore possible new drugs from existing classes and develop diagnostic tests specific to multidrug-resistant infections.

The comprehensive plan will call on a global core of economic, industry, intellectual, medical, philanthropic, political, regulatory and scientific leaders to meet research and development challenges.

IDSA researchers wrote that there are few candidate medications in the pipeline that offer benefits over existing drugs and few drugs moving forward that will treat the following infections: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species.

“The lack of new antibiotics in the pipeline threatens to leave physicians around the world without the tools they need to effectively treat patients, which could change the practice of medicine as we know it,” IDSA President Richard Whitley, MD, said in a press release. “Advances that we now take for granted, such as surgery, cancer treatment, transplants and the care of premature babies, could become impossible as our antibiotic options dwindle. If we can initiate a global commitment to achieve this 10 X ’20 goal, we will take a giant step toward protecting and ensuring the health of patients worldwide.”

The project is a collaboration involving the American Academy of Pediatrics, American Gastroenterological Association, Trust for America’s Health, the Society for Healthcare Epidemiology of America, the Pediatric Infectious Disease Society, the Michigan Antibiotic Resistance Reduction Coalition, the National Foundation for Infectious Diseases and the European Society of Clinical Microbiology and Infectious Diseases.

The European Union is also committed to the effort. The IDSA supports the creation of the transatlantic task force by President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt. The task force will focus on increasing the antibiotic pipeline and promoting antimicrobial stewardship in human and veterinary settings.

The IDSA said collaborative efforts among global stakeholders will incentivize sustainable research and development infrastructure. This infrastructure will, in turn, replenish a skilled scientific workforce that has steadily declined over the past two decades as a result of industry abandonment of antimicrobial development projects.


Adapted from materials provided by Infectious Disease News

Next Computer models could personalize medicine to prevent pandemics 2010-04-01 161802
Previous In Southeast community hospitals Clostridium difficile is more common than MRSA 2010-03-25 162710
޴ٷΰ ΰ